# Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas

> **NCT03532295** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 51 (actual)

## Conditions studied

- Glioma
- Glioblastoma

## Interventions

- **DRUG:** Epacadostat
- **DRUG:** Bevacizumab
- **RADIATION:** Radiation therapy
- **DRUG:** Retifanlimab

## Key facts

- **NCT ID:** NCT03532295
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-20
- **Primary completion:** 2024-07-26
- **Final completion:** 2025-10-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03532295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03532295, "Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03532295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*